期刊
CANCER JOURNAL
卷 16, 期 4, 页码 336-341出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e3181eb3879
关键词
human gene transfer; T-cell receptors (TCRs); chimeric antigen receptors (CARs); tumor regression
类别
资金
- Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline
Building on the principals that the adoptive transfer of T cells can lead to the regression of established tumors in humans, investigators are now further manipulating these cells using genetic engineering. Two decades of human gene transfer experiments have resulted in the translation of laboratory technology into robust clinical applications. The purpose of this review is to give the reader an introduction to the 2 major approaches being developed to redirect effector T-cell specificity. Primary human T cells can be engineered to express exogenous T-cell receptors or chimeric antigen receptors directed against multiple human tumor antigens. Initial clinical trial results have demonstrated that both T-cell receptor-and chimeric antigen receptor-engineered T cells can be administered to cancer patients and mediate tumor regression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据